| 39.87 Data as of May 17 |  +0.04 / +0.10%Today’s Change | 34.01 Today|||52-Week Range 58.00 | -13.87% Year-to-Date |
| Previous close | 39.83 |
| Today’s open | 39.93 |
| Day’s range | 39.79 - 40.37 |
| Volume | 108,993 |
| Average volume (3 months) | 100,642 |
| Market cap | $1.1B |
| Dividend yield | -- |
| Earnings growth (last year) | +77.86% |
| Earnings growth (this year) | -65.07% |
| Earnings growth (next 5 years) | +36.00% |
| Revenue growth (last year) | +612.51% |
| P/E ratio | NM |
| Price/Sales | 69.89 |
| Price/Book | 4.24 |
| Today’s change | Today’s % change | |
|---|---|---|
| HALOHalozyme Therapeutic... | -0.02 | -0.25% |
| ITMNInterMune Inc | -0.31 | -3.01% |
| IMGNImmunogen Inc | +0.21 | +1.31% |
| SZYMSolazyme Inc | +0.03 | +0.27% |
| Next reporting date | August 1, 2013 |
| EPS forecast (this quarter) | -$0.78 |
| Annual revenue (last year) | $15.0M |
| Annual profit (last year) | -$42.9M |
| Net profit margin | -287.21% |
Sector Health Technology |
Industry Biotechnology |
President, Chief Executive Officer & Director Sanj K. Patel |
Chief Financial Officer & Senior Vice President Carsten Boess |
Corporate headquarters Lexington, Massachusetts |
.
